Philippe Aftimos

Philippe Aftimos

UNVERIFIED PROFILE

Are you Philippe Aftimos?   Register this Author

Register author
Philippe Aftimos

Philippe Aftimos

Publications by authors named "Philippe Aftimos"

Are you Philippe Aftimos?   Register this Author

44Publications

1107Reads

13Profile Views

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Future Oncol 2019 Oct 20;15(28):3209-3218. Epub 2019 Aug 20.

UT Health San Antonio MD Anderson Cancer Center, Division of Hematology/Oncology 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0370DOI Listing
October 2019

Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases.

Eur J Surg Oncol 2019 Oct 12. Epub 2019 Oct 12.

Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1000, Brussels, Belgium; Centre de Chirurgie Hépato-Biliaire de l'ULB (CCHB-ULB), Université Libre de Bruxelles, 1070, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.10.016DOI Listing
October 2019

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Curr Treat Options Oncol 2019 Apr 1;20(5):37. Epub 2019 Apr 1.

Department of Research, Institut Jules Bordet; Université Libre de Bruxelles, Boulevard de Waterloo, 121 1000, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0633-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0633-6DOI Listing
April 2019

Network science in clinical trials: A patient-centered approach.

Semin Cancer Biol 2018 10 24;52(Pt 2):135-150. Epub 2017 Dec 24.

Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, ON, Canada; Department of Computer Science, University of Toronto, Toronto, ON, Canada; Ontario Institute of Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.12.006DOI Listing
October 2018

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

J Clin Oncol 2018 10 7;36(30):3007-3014. Epub 2018 May 7.

Jeremy Lewin and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Jean-Charles Soria and Christophe Massard, Institut Gustave Roussy and University Paris-Sud, Villejuif; Jean-Pierre Delord, Institut Claudius Regaud Oncopole, Toulouse; Mohamed Bekradda, Oncology Therapeutic Development, Clichy; Keyvan Rezai, Hôpital René Huguenin, Saint-Cloud, France; Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona; Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ahmad Awada and Philippe G. Aftimos, Université Libre de Bruxelles, Brussels, Belgium; and Zhen Zeng, Azher Hussain, and Susan Perez, Merck & Co, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2292DOI Listing
October 2018

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Anticancer Drugs 2016 11;27(10):1021-7

aJules Bordet Institute, Brussels, Belgium bGustave Roussy, Paris-Saclay University, Drug Development Department (DITEP), Villejuif, France cPharma Mar, S.A., Avenida de los Reyes, 1, Polígono Industrial La Mina-Norte, 28770 Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000409DOI Listing
November 2016

Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.

Expert Opin Emerg Drugs 2016 16;21(1):91-101. Epub 2016 Feb 16.

b Medical Oncology Clinic , Institut Jules Bordet, Université Libre de Bruxelles , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2016.1146680DOI Listing
October 2016

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Curr Opin Oncol 2016 09;28(5):441-6

aDepartment of Cancer Prevention, University of Texas MD Anderson Cancer Center Houston, Texas, USA bDepartment of Medicine, Medical Oncology Clinic, Institut Jules Bordet and University Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-oncology/2016/09000/Current_
Web Search
http://dx.doi.org/10.1097/CCO.0000000000000318DOI Listing
September 2016

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Anticancer Drugs 2016 Apr;27(4):342-8

aMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium bInstitut de Cancerologie de l'Ouest, Boulevard Jacques Monod, Nantes St-Herblain Cedex cDrug Development Department, Gustave Roussy Cancer Campus, Villejuif, Cedex dUniversity Paris Sud, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000336DOI Listing
April 2016

The current use and attitudes towards tumor genome sequencing in breast cancer.

Sci Rep 2016 Mar 2;6:22517. Epub 2016 Mar 2.

Department of Medicine, BrEAST Data Centre, Institut Jules Bordet/Université libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep22517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773754PMC
March 2016

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Jan 9;77(1):99-108. Epub 2015 Dec 9.

Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2914-5DOI Listing
January 2016

New generations of targeted therapies fighting the resistance in solid tumors.

Curr Opin Oncol 2015 May;27(3):243-9

aMedical Oncology Clinic, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium bDépartement d'Oncologie médicale et d'hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000175DOI Listing
May 2015

Evolving paradigms in multifocal breast cancer.

Semin Cancer Biol 2015 Apr 24;31:111-8. Epub 2014 Jul 24.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2014.07.002DOI Listing
April 2015

Successful treatment of Evans syndrome with Tacrolimus.

Invest New Drugs 2015 Feb 12;33(1):254-6. Epub 2014 Sep 12.

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-014-0155
Web Search
http://link.springer.com/10.1007/s10637-014-0155-9
Publisher Site
http://dx.doi.org/10.1007/s10637-014-0155-9DOI Listing
February 2015

Cardiotoxicity of systemic agents used in breast cancer.

Breast 2014 Aug 1;23(4):317-28. Epub 2014 May 1.

Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.04.002DOI Listing
August 2014

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Expert Rev Anticancer Ther 2014 Jun;14(6):649-65

Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.920693DOI Listing
June 2014

Anticancer drug development: moving away from the old habits.

Curr Opin Oncol 2014 May;26(3):334-9

aMedical Oncology Clinic bBreast International Group Headquarters (BIG-aisbl), Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000076DOI Listing
May 2014

Impact of tumor sequencing on the use of anticancer drugs.

Curr Opin Oncol 2014 May;26(3):347-56

aThomas Conseil SPRL bBreast Cancer Translational Research Laboratory, Institut Jules Bordet cDepartment of Medicine, Medical Oncology Clinic, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CCO.0000000000000078DOI Listing
May 2014

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine.

Discov Med 2014 Feb;17(92):81-91

Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
February 2014

Targeted therapies of solid cancers: new options, new challenges.

Curr Opin Oncol 2013 May;25(3):296-304

Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835ff318DOI Listing
May 2013

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Curr Opin Oncol 2012 May;24(3):297-304

Medical Oncology Clinic, Institut Jules Bordet-Université libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e3283521349DOI Listing
May 2012

[Chemoradiotherapy in early stage Hodgkin's lymphoma].

J Med Liban 2011 Jul-Sep;59(3):122-5

Services de Radiothérapie oncologique, Hôtel-Dieu de France, Beyrouth, Liban.

View Article

Download full-text PDF

Source
March 2012

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Adv Ther 2011 Nov 19;28(11):973-85. Epub 2011 Oct 19.

Medical Oncology Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-011-0070-9DOI Listing
November 2011

Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.

Radiat Oncol 2010 Jun 4;5:50. Epub 2010 Jun 4.

Hematology - Oncology Department, Hotel Dieu de France University Hospital, Alfred Naccache BLVD, Achrafieh, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1748-717X-5-50DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887890PMC
June 2010

Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation.

Leuk Res 2010 Mar 11;34(3):406-8. Epub 2009 Aug 11.

Hematology and Medical Oncology Department, Hotel-Dieu de France University Hospital, Alfred Naccache Boulevard, Achrafieh, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2009.07.025DOI Listing
March 2010